Journal of Clinical Psychopharmacology

Home
Journal of Clinical Psychopharmacology

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Journal of Clinical Psychopharmacology, Media/News Company, .

Journal of Clinical Psychopharmacology, a leading publication in psychopharmacology, offers a wide range of articles reporting on clinical trials and studies, side effects, drug interactions, overdose management, pharmacogenetics, pharmacokinetics, and psychiatric effects of non-psychiatric drugs. The journal keeps clinician-scientists and trainees up-to-date on the latest clinical developments in

psychopharmacologic agents, presenting the extensive coverage needed to keep up with every development in this fast-growing field.

05/09/2025

A presidential executive order early this year directed federal departments and agencies to address the issue of chronic disease in the United States, including “the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors,” with a particular focus on youth. Our latest editorial and podcast revisit the evidence: SSRIs remain safe, effective, and essential for many youth with anxiety, depression, and OCD. The authors, Drs. Jeffrey Strawn and John Walkup, caution that the framing of the issue in the executive order risks reinforcing stigma and diminishing trust in evidence-based pediatric mental health care.
🎧 Listen to the podcast: https://jcpjournal.libsyn.com/fact-versus-fear-antidepressants-in-children-and-adolescents
📰 Read the guest editorial: https://journals.lww.com/psychopharmacology/pages/articleviewer.aspx?year=2025&issue=09000&article=00001&type=Fulltext

03/09/2025

Many patients view the return of “positive mental health” (PMH) to be their most important goal of treatment for major depressive disorder (MDD). However, few studies have systematically measured PMH or prospectively examined the added value of considering PMH as a treatment predictor of outcomes. In our new podcast, Dr. Somaia Mohamed of Yale University discusses her article, “How Does Positive Mental Health Affect Next-Step Treatment Outcomes in Treatment-Resistant Depression? A VAST-D Report.” Dr. Mohamed and her coauthors found that high PMH scores at baseline were associated with a greater chance of remission.
🎧 Listen to podcast: https://jcpjournal.libsyn.com/how-does-positive-mental-health-affect-next-step-treatment-outcomes-in-treatment-resistant-depression
📰 Read the article: https://journals.lww.com/psychopharmacology/fulltext/2025/09000/how_does_positive_mental_health_affect_next_step.3.aspx

28/08/2025

Our September/October 2025 issue (Volume 45, issue 5) is now available online: https://journals.lww.com/psychopharmacology/pages/currenttoc.aspx

Brief synopsis of the new issue from the Journal of Clinical Psychopharmacology Editor-in-Chief is below.

25/08/2025

A new case in JCP details extreme nonmedical use of tranylcypromine: a patient took up to 2400 mg/day over nearly 10 years, far exceeding safe limits. The report underscores the drug’s abuse potential and the urgent need for careful monitoring in complex psychiatric cases. Read more: https://journals.lww.com/psychopharmacology/fulltext/2025/07000/exploring_the_addictive_potential_of.20.aspx

22/08/2025

A new systematic review in JCP explores the potential of and supplementation to support treatment of psychiatric symptoms. Preliminary evidence suggests benefits for mood, anxiety, and obsessive-compulsive symptoms, particularly in individuals with nutritional deficits or metabolic dysfunction.
Read more on this topic in our current issue: https://journals.lww.com/psychopharmacology/fulltext/2025/07000/the_potential_benefits_of_chromium_and_selenium.12.aspx

20/08/2025

Glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed to treat type 2 diabetes and obesity, are emerging as a promising therapeutic strategy for alcohol use disorder due to their influence on brain reward pathways. A new systematic review article in our current issue synthesizes existing preclinical and clinical evidence on the effects of GLP-1 receptor agonists on alcohol-related behaviors and consumption. Read more: https://journals.lww.com/psychopharmacology/fulltext/2025/07000/the_role_of_glucagon_like_peptide_1_receptor.11.aspx

15/08/2025

A recent open-label trial found that methylphenidate significantly improved emotion dysregulation in most children, but for those who didn’t respond, aripiprazole — either alone or in combination — proved effective.

Read more in our current issue: https://journals.lww.com/psychopharmacology/fulltext/2025/07000/the_role_of_methylphenidate_and_aripiprazole_in.9.aspx

13/08/2025

In a real-world study of 20,000+ patients with major depressive disorder, pharmacogenomic testing was linked to a 39% reduction in prescribing of medications with significant gene-drug interactions and fewer psychiatric hospitalizations and ED visits. These findings highlight the potential of PGx-guided care to improve outcomes and reduce healthcare burden. Read more: https://journals.lww.com/psychopharmacology/fulltext/2025/07000/real_world_impact_of_pharmacogenomic_testing_on.3.aspx

11/08/2025

Can a patient's family history of medication response help guide treatment for mood disorders? Although this approach is widely used and recommended, a new systematic review finds that the supporting evidence is limited. More rigorous research is needed to validate this common clinical practice. Read the full article and listen to our accompanying podcast to learn more.
📘 https://journals.lww.com/psychopharmacology/fulltext/2025/07000/a_systematic_review_to_determine_if_family_history.10.aspx
🎧 https://jcpjournal.libsyn.com/a-systematic-review-to-determine-if-family-history-of-response-to-medication-predicts-outcome-in-mood-disorders

06/08/2025

Are doctors being subtly influenced by the industry's hidden ? A new guest editorial and podcast by Dr. Jeffrey Mattes explores how pharmaceutical companies may be shaping physician behavior — not just through traditional promotion, but also by influencing e-prescribing alerts and drug interaction databases. The piece raises critical questions about transparency, evidence, and the subtle power of marketing in clinical decision-making.
🎧 Podcast: https://jcpjournal.libsyn.com/how-does-drug-company-marketing-affect-physician-prescribing
📰 Editorial: https://journals.lww.com/psychopharmacology/fulltext/2025/07000/how_does_drug_company_marketing_affect_physician.1.aspx

29/07/2025

A new retrospective study of 14 pregnancies in women with schizophrenia treated with clozapine found a 36% miscarriage rate, but no congenital malformations among live births, normal infant growth, and no adverse effects during breastfeeding.
🔗 Read more in our current issue: https://journals.lww.com/psychopharmacology/fulltext/2025/07000/use_of_clozapine_in_pregnancy__a_retrospective.8.aspx

23/07/2025

A newly published case report in JCP presents what may be the first documented instance of a manic episode potentially triggered by primidone in a patient with essential tremor and a history of depression. Read the full case to explore potential mechanisms and implications for treatment safety and monitoring: https://journals.lww.com/psychopharmacology/fulltext/2025/07000/manic_switch_associated_with_primidone_in_a.14.aspx

Address

Website

http://www.psychopharmacology.com/

Alerts

Be the first to know and let us send you an email when Journal of Clinical Psychopharmacology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your business to be the top-listed Media Company?

Country:

City: